Key references: Duration of pharmacotherapy for attention deficit hyperactivity disorder in children

  • Bolea-Alamanac B, Nutt DJ, Adamou M, Asherson P, Bazire S, Coghill D, et al. Evidence-based guidelines for the pharmacological management of attention deficit hyperactivity disorder: update on recommendations from the British Association for Psychopharmacology. J Psychopharmacol 2014;28(3):179–203. https://www.ncbi.nlm.nih.gov/pubmed/24526134
  • Canadian ADHD Resource Alliance (CADDRA). Canadian ADHD practice guidelines. 4th ed. Toronto, ON: CADDRA; 2018. http://www.caddra.ca/canadian-adhd-practice-guidelines/
  • National Institute for Health and Clinical Excellence (NICE). Attention deficit hyperactivity disorder: diagnosis and management (NG87). London: NICE; 2018. https://www.nice.org.uk/guidance/NG87
  • Taylor E, Dopfner M, Sergeant J, Asherson P, Banaschewski T, Buitelaar J, et al. European clinical guidelines for hyperkinetic disorder -- first upgrade. Eur Child Adolesc Psychiatry 2004;13 Suppl 1:I7–30. https://www.ncbi.nlm.nih.gov/pubmed/15322953
  • Wolraich ML, Hagan JF, Allan C, Chan E, Davison D, Earls M, et al. Clinical practice guideline for the diagnosis, evaluation, and treatment of attention-deficit/hyperactivity disorder in children and adolescents. Pediatrics 2019;144(4). https://www.ncbi.nlm.nih.gov/pubmed/31570648